Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 0.59 |
| ▸ | DRD1 known ✓ | P21728 | 8/20 | 0.59 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.49 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.49 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.49 |
| ▸ | DRD5 | P21918 | 8/20 | 0.59 |
| ▸ | DRD3 | P35462 | 6/20 | 0.59 |
| ▸ | DRD4 | P21917 | 4/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL12467794 | 1.00 | DRD2 (0.59) | DRD2DRD1DRD5DRD3DRD4 | |
| Maleic Acid SCHEMBL29935486 | 0.87 | HTT (0.50) | DRD2DRD1DRD5DRD3DRD4 | |
| Fumaric Acid SCHEMBL11488028 | 0.83 | CYP3A4 (0.50) | DRD2DRD1DRD5DRD3DRD4 | |
| Maleic Acid SCHEMBL11488022 | 0.83 | CYP3A4 (0.50) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL29391320 | 0.81 | DRD1 (0.85) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL164206 | 0.81 | DRD1 (0.85) | DRD2DRD1DRD5DRD3DRD4 | |
| Succinic Acid SCHEMBL170445 | 0.81 | DRD2 (0.64) | DRD2DRD1DRD5DRD3DRD4 | |
| Setiptiline SCHEMBL623015 | 0.81 | DRD1 (0.76) | DRD2DRD1DRD5DRD3DRD4 | |
| Fumaric Acid SCHEMBL10702746 | 0.81 | SMN1; SMN2 (0.51) | DRD2DRD1DRD5DRD3DRD4 | |
| Setiptiline SCHEMBL29396748 | 0.81 | DRD1 (0.76) | DRD2DRD1DRD5DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |